Edition:
United States

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

32.96USD
24 May 2017
Change (% chg)

$1.06 (+3.32%)
Prev Close
$31.90
Open
$31.83
Day's High
$33.58
Day's Low
$31.58
Volume
659,657
Avg. Vol
833,176
52-wk High
$36.13
52-wk Low
$5.72

Latest Key Developments (Source: Significant Developments)

Exact Sciences posts Q1 loss per share $0.32
Thursday, 27 Apr 2017 06:00am EDT 

April 27 (Reuters) - Exact Sciences Corp :Q1 loss per share $0.32.Sees FY 2017 revenue $195 million to $205 million.Q1 revenue $48.4 million versus $14.8 million.Exact Sciences Corp - company anticipates revenue of $195 million-$205 million and completed Cologuard test volume of at least 470,000 tests during 2017.  Full Article

Mdxhealth and Exact Sciences sign collaboration agreement
Thursday, 27 Apr 2017 01:00am EDT 

April 27 (Reuters) - Mdxhealth Sa : :Mdxhealth and Exact Sciences sign collaboration agreement for collaboration in the growing field of epigenetics and molecular diagnostics.These acquisitions include one-time fees totaling $15 million, including payments accrued since July 2016.Exact Sciences is also acquiring Mdxhealth patents directed toward colorectal cancer.  Full Article

Exact sciences Q4 loss per share $0.34
Tuesday, 21 Feb 2017 06:00am EST 

Exact Sciences Corp : Q4 loss per share $0.34 . Sees FY 2017 revenue $170 million to $180 million . Q4 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S . Q4 revenue $35.2 million versus i/b/e/s view $33.2 million . Exact Sciences Corp - during Q1 of 2017, company expects cologuard volume of at least 88,000 completed tests . Exact Sciences Corp - company anticipates cologuard volume of at least 415,000 completed tests during 2017 .FY2017 revenue view $163.2 million -- Thomson Reuters I/B/E/S.  Full Article

Exact Sciences says Cologuard included in medicare advantage advance notice, draft call letter
Thursday, 2 Feb 2017 06:00am EST 

Exact Sciences Corp :Exact Sciences Corp says that Cologuard is included in medicare advantage advance notice and draft call letter.  Full Article

Exact Sciences Q3 loss per share $0.36
Wednesday, 26 Oct 2016 06:00am EDT 

Exact Sciences Corp : Q3 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S . Exact sciences Corp- revenues of $28.1 million during Q3 ended Sept. 30, 2016, an increase of 123 percent from $12.6 million in Q3 of 2015 . Q3 revenue view $25.3 million -- Thomson Reuters I/B/E/S . Says expects cologuard tests volume will deliver full-year 2016 revenues in range of $93-95 million .FY2016 revenue view $90.9 million -- Thomson Reuters I/B/E/S.  Full Article

David Shaw reports 5 pct passive stake in Exact Sciences Corp - SEC filing
Thursday, 25 Aug 2016 04:05pm EDT 

Exact Sciences Corp :David shaw reports 5 pct passive stake in Exact Sciences Corp - SEC filing.  Full Article

Exact Sciences files for potential mixed shelf - SEC filing
Wednesday, 27 Jul 2016 04:08pm EDT 

Exact Sciences Corp :Files for potential mixed shelf - SEC filing.  Full Article

Exact Sciences posts Q2 loss per share of $0.46
Tuesday, 26 Jul 2016 05:00am EDT 

Exact Sciences Corp : Generated revenues of $21.2 million during Q2 ended June 30, 2016, representing a 161-percent increase from $8.1 million in Q2 of 2015 . Q2 loss per share $0.46 . Continues to anticipate completing more than 240,000 Cologuard tests during 2016, generating revenue of $90 to $100 million for 2016 . Q2 earnings per share view $-0.55, revenue view $18.5 million -- Thomson Reuters I/B/E/S .FY2016 revenue view $86.6 million -- Thomson Reuters I/B/E/S.  Full Article

Exact Sciences'Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations
Wednesday, 15 Jun 2016 02:37pm EDT 

: Exact Sciences' Cologuard Included in Final USPSTF Colorectal Cancer Screening Recommendations .Exact Sciences Corp says final recommendations also recognize use of cologuard every three years.  Full Article

Exact Sciences Corp announces contract with Anthem BlueCross of California
Monday, 11 Jan 2016 06:15am EST 

Exact Sciences Corp:Says signed agreement with Anthem in California contemplates that Exact Sciences may enter into similar agreements with Anthem affiliates in other regions, and Exact Sciences intends to pursue such agreements during the first half of 2016.  Full Article

More From Around the Web

BRIEF-Exact Sciences posts Q1 loss per share $0.32

* Exact Sciences Corp - company anticipates revenue of $195 million-$205 million and completed Cologuard test volume of at least 470,000 tests during 2017 Source text for Eikon: Further company coverage: